Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345–59. https://doi.org/10.1038/s41568-021-00347-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5. https://doi.org/10.1126/science.aar6711.

Article  CAS  PubMed  Google Scholar 

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45–56. https://doi.org/10.1056/NEJMoa1804980.

Article  CAS  PubMed  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531–44. https://doi.org/10.1056/NEJMoa1707447.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491–502. https://doi.org/10.1016/S0140-6736(21)01222-8.

Article  CAS  PubMed  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52. https://doi.org/10.1016/S0140-6736(20)31366-0.

Article  PubMed  Google Scholar 

Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384:705–16. https://doi.org/10.1056/NEJMoa2024850.

Article  CAS  PubMed  Google Scholar 

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24. https://doi.org/10.1016/S0140-6736(21)00933-8.

Article  CAS  PubMed  Google Scholar 

Newick K, O’Brien S, Moon E, Albelda SM. CAR T Cell Therapy for Solid Tumors. Annu Rev Med. 2017;68:139–52. https://doi.org/10.1146/annurev-med-062315-120245.

Article  CAS  PubMed  Google Scholar 

Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019;10:128. https://doi.org/10.3389/fimmu.2019.00128.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shimabukuro-Vornhagen A, Böll B, Schellongowski P, Valade S, Metaxa V, Azoulay E, et al. Critical care management of chimeric antigen receptor T-cell therapy recipients. CA Cancer J Clin. 2022;72:78–93. https://doi.org/10.3322/caac.21702.

Article  PubMed  Google Scholar 

Azoulay É, Castro P, Maamar A, Metaxa V, de Moraes AG, Voigt L, et al. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol. 2021;8:e355-64. https://doi.org/10.1016/S2352-3026(21)00060-0.

Article  CAS  PubMed  Google Scholar 

Shao F, Long Y, Ji H, Jiang D, Lei P, Lan X. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring. Theranostics. 2021;11:6800–17. https://doi.org/10.7150/thno.56989.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minn I, Rowe SP, Pomper MG. Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. Lancet Oncol. 2019;20:e443–51. https://doi.org/10.1016/S1470-2045(19)30461-9.

Article  CAS  PubMed  Google Scholar 

Kaur T, Upadhyay J, Pukale S, Mathur A, Ansari MN. Investigation of Trends in the Research on Transferrin Receptor-Mediated Drug Delivery via a Bibliometric and Thematic Analysis. Pharmaceutics. 2022;14:2574. https://doi.org/10.3390/pharmaceutics14122574.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo Z, Zhang Y, Fu M, Zhao L, Wang Z, Xu Z, et al. The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies. Front Immunol. 2021;12:652924. https://doi.org/10.3389/fimmu.2021.652924.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72:524–41. https://doi.org/10.3322/caac.21754.

Article  PubMed  Google Scholar 

Walker RA, Day SJ. Transferrin receptor expression in non-malignant and malignant human breast tissue. TJ Pathol. 1986;148:217–24. https://doi.org/10.1002/path.1711480305.

Article  CAS  Google Scholar 

Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat. 2010;119:283–93. https://doi.org/10.1007/s10549-009-0345-x.

Article  CAS  PubMed  Google Scholar 

Ling Y, Wang W, Hao L, Wu X, Liang J, Zhang H, et al. Self-Amplifying Iridium(III) Photosensitizer for Ferroptosis-Mediated Immunotherapy Against Transferrin Receptor-Overexpressing Cancer. Small. 2022;18:e2203659. https://doi.org/10.1002/smll.202203659.

Article  CAS  PubMed  Google Scholar 

Fu M, He Q, Guo Z, Zhou X, Li H, Zhao L, et al. Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor. Front Immunol. 2019;10:1396. https://doi.org/10.3389/fimmu.2019.01396.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang G, Kumar A, Ding W, Korangath P, Bera T, Wei J, et al. Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study. Proc Natl Acad Sci U S A. 2022;119:e2200200119. https://doi.org/10.1073/pnas.2200200119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92:897–965. https://doi.org/10.1152/physrev.00049.2010.

Article  CAS  PubMed  Google Scholar 

Rowe SP, Pomper MG. Molecular imaging in oncology: Current impact and future directions. CA Cancer J Clin. 2022;72:333–52. https://doi.org/10.3322/caac.21713.

Article  PubMed  Google Scholar 

Sakemura R, Can I, Siegler EL, Kenderian SS. In vivo CART cell imaging: Paving the way for success in CART cell therapy. Mol Ther Oncolytics. 2021;20:625–33. https://doi.org/10.1016/j.omto.2021.03.003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minn I, Huss DJ, Ahn HH, Chinn TM, Park A, Jones J, et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Sci Adv. 2019;5:eaaw5096. https://doi.org/10.1126/sciadv.aaw5096.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vedvyas Y, Shevlin E, Zaman M, Min IM, Amor-Coarasa A, Park S, et al. Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight. 2016;1:e90064. https://doi.org/10.1172/jci.insight.90064.

Article  PubMed  PubMed Central  Google Scholar 

Moroz MA, Zhang H, Lee J, Moroz E, Zurita J, Shenker L, et al. Comparative Analysis of T Cell Imaging with Human Nuclear Reporter Genes. J Nucl Med. 2015;56:1055–60. https://doi.org/10.2967/jnumed.115.159855.

Article  CAS  PubMed  Google Scholar 

Sellmyer MA, Richman SA, Lohith K, Hou C, Weng CC, Mach RH, et al. Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene. Mol Ther. 2020;28:42–51. https://doi.org/10.1016/j.ymthe.2019.10.007.

Article  CAS  PubMed  Google Scholar 

Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med. 2017;9:eaag2196. https://doi.org/10.1126/scitranslmed.aag2196.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Volpe A, Lang C, Lim L, Man F, Kurtys E, Ashmore-Harris C, et al. Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models. Mol Ther. 2020;28:2271–85. https://doi.org/10.1016/j.ymthe.2020.06.028.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krebs S, Ahad A, Carter LM, Eyquem J, Brand C, Bell M, et al. Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. J Nucl Med. 2018;59:1894–900. https://doi.org/10.2967/jnumed.118.208041.

Article